Review article · 6 Jul 2016
CommentaryPublished 16 Nov 2020
PCSK9 Inhibitors or Ezetimibe as the Second Line Add-on to Statin Therapy
Subjects
General & Internal MedicineSimilar by topic
Editorial · 21 Jul 2016
Beyond lipid-lowering therapy: does ezetimibe enhance the effects of statins on atherosclerosis?
Research article · 30 Jun 2022
Therapeutic Efficacy and Long-term Treatment Outcome of DPP-4 Inhibitors as an add-on Therapy with Metformin and Sulfonylureas in T2DM Patients at GP Clinics of Southern Odisha
Research article · 2016
Dipeptidyl Peptidase-4 Inhibitor Switching as an Alternative Add-on Therapy to Current Strategies Recommended by Guidelines: Analysis of a Retrospective Cohort of Type 2 Diabetic Patients
Research article · 26 Jun 2020
Efficacy and Safety of Dapagliflozin 10 mg as Add-on to Metformin versus Metformin with or without Other Hypoglycemic Agents in Type 2 Diabetes Mellitus Patients, Retrospective Observational Study
More from this journal
The newest in Archives of Medicine.
Perspective · 29 Jan 2025
Pharmacogenomics in toxicology: Tailoring antidotes to genetic profiles
Perspective · 29 Jan 2025
Early-life nutrition and its impact on pediatric immune development
Commentary · 29 Jan 2025
Polypharmacy in the aging population: Risks, benefits and alternatives
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives of Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Aniruddha Singh”

